Press Releases

New Data Presented at ADA Demonstrate Early Effect of EndoBarrier Therapy on Glucose Control and Bile Acid Regulators

Oral and poster presentations at American Diabetes Association annual meeting reinforce value of duodenal-jejunal exclusion for treating type 2 diabetes and obesity June 08, 2015 08:30 AM Eastern Daylight Time LEXINGTON, Mass. & SYDNEY–(BUSINESS WIRE)–GI Dynamics, Inc. (ASX: GID),...

read more

2015 Annual Meeting of Stockholders Access for Participants by Webcast and Conference Call

LEXINGTON, Massachusetts, United States and SYDNEY, Australia – 27 May 2015 – GI Dynamics, Inc. (ASX: GID) (GI Dynamics or the Company) will hold its 2015 Annual Meeting of Stockholders on Tuesday, June 9, 2015 at 9:00 a.m. Australian Eastern Standard Time (which is 7:00 p.m. on Monday, June 8,...

read more

GI Dynamics Announces Results of First Comparative Study of Gastric Bypass and EndoBarrier® Therapy on Diabetes Remission at Digestive Disease Week 2015

LEXINGTON, Mass. & SYDNEY–(BUSINESS WIRE)–GI Dynamics, Inc. (ASX: GID), a medical device company providing innovative treatments for type 2 diabetes and obesity, today announced data showing improvement in glucose metabolism following treatment with EndoBarrier® Therapy...

read more

Appendix 4C Quarterly Report Quarter Ended 31 March 2015

LEXINGTON, Massachusetts, United States and SYDNEY, Australia–(BUSINESS WIRE)–GI Dynamics, Inc. (ASX: GID) (GI Dynamics or the Company), a medical device company developing innovative treatments for type 2 diabetes and obesity, is pleased to provide its financial results for the...

read more

ENDO Trial Placed on Enrollment Hold

LEXINGTON, Mass & SYDNEY–(BUSINESS WIRE)–GI Dynamics, Inc. (ASX: GID) (GI Dynamics or the Company), a medical device company developing innovative treatments for type 2 diabetes and obesity, announced today that the U.S. Food and Drug Administration (FDA) has placed a hold on...

read more

Appendix 4C Quarterly Report Quarter ended 31 December 2014

LEXINGTON, Massachusetts, United States and SYDNEY, Australia – 30 January 2015 – GI Dynamics, Inc. (ASX: GID) (GI Dynamics or the Company), a medical device company developing innovative treatments for type 2 diabetes and obesity, is pleased to provide its financial results for the quarter ended...

read more

GI Dynamics, Inc. Announces Corporate Restructuring and Departure of Chief Financial Officer

LEXINGTON, Massachusetts & SYDNEY, Australia – 8 December 2014 – GI Dynamics, Inc. (ASX: GID) a medical device company developing innovative treatments for type 2 diabetes and obesity, today announced that the Company and Robert W. Crane, its chief financial officer, secretary and treasurer,...

read more

GI Dynamics, Inc. Announces Corporate Restructuring and Departure of Chief Financial Officer

LEXINGTON, Massachusetts & SYDNEY, Australia – 8 December 2014 – GI Dynamics, Inc. (ASX: GID) a medical device company developing innovative treatments for type 2 diabetes and obesity, today announced that the Company and Robert W. Crane, its chief financial officer, secretary and treasurer,...

read more

GI Dynamics Resumes Shipments of EndoBarrier® Product

Notified Body, following review, clears Company to resume shipments LEXINGTON, Massachusetts – 1 December 2014 – GI Dynamics, Inc. (ASX: GID), a medical device company developing innovative treatments for type 2 diabetes and obesity, today announced that its Notified Body in the European Union, an...

read more

GI Dynamics to Present at the 26th Annual Piper Jaffray Healthcare Conference

LEXINGTON, Massachusetts & SYDNEY, Australia – 19 November 2014 – GI Dynamics, Inc. (ASX: GID), a medical device company developing innovative treatments for type 2 diabetes and obesity, today announced that Michael Dale, president and chief executive officer, is scheduled to present at the...

read more
Page 5 of 18« First...34567...10...Last »